Aptamer Sciences Inc (291650.KQ) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · South Korea

Price
2,365.00 KRW
Market cap
72.18 bn KRW
P/E (2025)
–
P/S (2025)
20.59
Dividend yield
0.00 %
Net margin
-245.98 %
Return on equity (ROE)
-30.54 %
Return on assets (ROA)
-20.97 %

Aptamer Sciences Inc financials

Fiscal year20242025
Revenue1.08 bn KRW3.50 bn KRW
Gross profit-1.63 bn KRW1.69 bn KRW
Operating income-6.87 bn KRW-7.80 bn KRW
EBIT-7.35 bn KRW-8.30 bn KRW
Net income-8.70 bn KRW-8.62 bn KRW
Diluted EPS – continuing operations-297.21 KRW-428.33 KRW

Full history since 2018, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Aptamer Sciences Inc

CHOOLIP & SCIENCES Inc., a bio venture company, focuses on the Aptamer technology platform for the development of therapeutic and diagnostic platforms. The company's platforms include aptamer discovery, optimization, and the development of therapeutics and diagnostics for cancer and neurological disorders. It offers AlloMAp and Bi-Functional Aptame (BiFAp) platform programs for therapeutics, as well as Aptodetect-lung, an early diagnosis kit for lung cancer. The company was formerly known as Aptamer Sciences Inc and changed its name to CHOOLIP & SCIENCES Inc. in August 2026. CHOOLIP & SCIENCES Inc. was founded in 2011 and is headquartered in Seongnam-si, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.